Ligand Pharma (NASDAQ:LGND) reported Q4 EPS of $1.36, $0.49 better than the analyst estimate of $0.87. Revenue for the quarter came in at $50.38 million versus the consensus estimate of $44.09 million.
Ligand Pharma (NASDAQ:LGND) reported Q4 EPS of $1.36, $0.49 better than the analyst estimate of $0.87. Revenue for the quarter came in at $50.38 million versus the consensus estimate of $44.09 million.